Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial
Journal of the American Academy of Dermatology · 2026
DOI: 10.1016/j.jaad.2025.09.044 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Academy of Dermatology, 2026. Verfasst von Cheng Zhou und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Alopecia Areata, Janus Kinase 1. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Jiangsu Hengrui Medicine.
Abstract (Originalsprache)
BACKGROUND: Ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, demonstrated efficacy in a phase 2 trial for moderate-to-severe alopecia areata (AA). OBJECTIVE: To evaluate the efficacy and safety of ivarmacitinib in adults with severe AA (≥50% scalp hair loss, including alopecia totalis/universalis). METHODS: In this randomized, double-blind, phase 3 trial, 330 patients were assigned (1:1:1) to ivarmacitinib 4 mg, 8 mg, or placebo once daily for 24 weeks. Placebo recipients were re-randomized to ivarmacitinib for a 28-week extension. The primary endpoint was the proportion achieving a Severity of Alopecia Tool (SALT) score ≤20 at week 24. RESULTS: At week 24, SALT ≤20 was achieved by 34.9% (4 mg), 40.6% (8 mg), and 9.0% (placebo). Absolute differences versus placebo were 25.6% (95% CI: 15.4-35.7) for 4 mg and 31.6% (21.5-41.8) for 8 mg (both P < .0001). Treatment-emergent adverse events occurred in 77.1%, 84.7%, and 75.5% of patients, respectively; most were mild or moderate. No deaths, major cardiovascular events, or thromboembolic events were reported. LIMITATION: No active comparator was used. CONCLUSION: Once-daily ivarmacitinib 4 mg or 8 mg resulted in meaningful hair regrowth and demonstrated an acceptable safety profile in patients with severe AA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Peking University People's Hospital, Beijing, China.
- Department of Dermatology and Venereology, The Second Hospital of Anhui Medical University, Hefei, China.
- Department of Dermatology, Jiangsu People's Hospital, Nanjing, China.
- Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, China.
- Department of Dermatology and Venereology, China-Japan Friendship Hospital, Beijing, China.
- Department of Dermatology and Venereology, Peking Union Medical College Hospital, Beijing, China.
Förderung
- Jiangsu Hengrui Medicine
Zitieren
APA
Zhou, C., Yang, C., Fan, W., Wu, J., Yang, D., Jin, H., Yang, Q., Hu, G., Lin, N., Yang, X., Wan, J., Zhang, J., Wu, L., Dai, Y., Ma, L., Li, S., Su, J., Sun, J., Ding, Y., …, & Zhang, J. (2026). Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2025.09.044
Vancouver
Zhou C, Yang C, Fan W, Wu J, Yang D, Jin H, et al. Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial. Journal of the American Academy of Dermatology. 2026. doi:10.1016/j.jaad.2025.09.044
BibTeX
@article{Zhou2026,
author = {Zhou, Cheng and Yang, Chunjun and Fan, Weixin and Wu, Jiyuan and Yang, Dingquan and Jin, Hongzhong and Yang, Qinping and Hu, Guohong and Lin, Nengxing and Yang, Xiumin and Wan, Jianji and Zhang, Jianglin and Wu, Liming and Dai, Yeqin and Ma, Lili and Li, Shanshan and Su, Juan and Sun, Jianfang and Ding, Yangfeng and Xiao, Rong and Zhang, Su and Jiang, Wenwen and Wang, Lihao and Zhang, Jianzhong},
title = {Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
doi = {10.1016/j.jaad.2025.09.044}
}
EUVIMED